HRP Anti-FOXP3 antibody [mAbcam 22510] (ab22831)
Key features and details
- HRP Mouse monoclonal [mAbcam 22510] to FOXP3
- Suitable for: WB
- Reacts with: Human
- Conjugation: HRP
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
HRP Anti-FOXP3 antibody [mAbcam 22510]
See all FOXP3 primary antibodies -
Description
HRP Mouse monoclonal [mAbcam 22510] to FOXP3 -
Host species
Mouse -
Conjugation
HRP -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide corresponding to Human FOXP3 aa 400 to the C-terminus.
(Peptide available asab16809) -
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 1% BSA, 30% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
IgG fraction -
Clonality
Monoclonal -
Clone number
mAbcam 22510 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Recombinant Protein
-
Related Products
- TMB ELISA Substrate (Highest Sensitivity) (ab171522)
- TMB ELISA Substrate (High Sensitivity) (ab171523)
- TMB ELISA Substrate (Fast Kinetic Rate) (ab171524)
- TMB ELISA Substrate (Slow Kinetic Rate) (ab171525)
- TMB ELISA Substrate (Slower Kinetic Rate) (ab171526)
- TMB ELISA Substrate (Slowest Kinetic Rate) (ab171527)
- 450 nm Stop Solution for TMB Substrate (ab171529)
- 650 nm Stop Solution for TMB Substrate (ab171531)
- Immunoassay Blocking Buffer (ab171534)
- Immunoassay Blocking (BSA Free) (ab171535)
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab22831 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/1000. Detects a band of approximately 50 kDa (predicted molecular weight: 50 kDa).
|
Notes |
---|
WB
1/1000. Detects a band of approximately 50 kDa (predicted molecular weight: 50 kDa). |
Target
-
Function
Probable transcription factor. Plays a critical role in the control of immune response. -
Involvement in disease
Defects in FOXP3 are the cause of immunodeficiency polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) [MIM:304790]; also known as X-linked autoimmunity-immunodeficiency syndrome. IPEX is characterized by neonatal onset insulin-dependent diabetes mellitus, infections, secretory diarrhea, trombocytopenia, anemia and eczema. It is usually lethal in infancy. -
Sequence similarities
Contains 1 C2H2-type zinc finger.
Contains 1 fork-head DNA-binding domain. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 50943 Human
- Omim: 300292 Human
- SwissProt: Q9BZS1 Human
- Unigene: 247700 Human
-
Alternative names
- AIID antibody
- DIETER antibody
- Forkhead box P3 antibody
see all
Images
-
All lanes : HRP Anti-FOXP3 antibody [mAbcam 22510] (ab22831) at 1/1000 dilution
Lane 1 : HEK 293 cells overexpressing human FOXP3
Lane 2 : HEK 293 cells overexpressing human FOXP3 with Human FOXP3 peptide (ab16809) at 1 µg/ml
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 50 kDa
Observed band size: 50 kDa
Exposure time: 3 minutes
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab22831 has not yet been referenced specifically in any publications.